Atossa Therapeutics精简Evangeline乳腺癌临床试验 优先推进2026年新药申请相关工作

美股速递
Oct 06, 2025

Atossa Therapeutics公司宣布将对其Evangeline乳腺癌临床试验项目进行精简调整,以便将资源重点投入到2026年新药申请(NDA)的相关准备工作中。

该公司此举旨在优化临床试验流程,确保能够按计划推进新药申请进程,为患者尽早提供治疗选择。通过精简试验设计,Atossa Therapeutics希望能够更高效地收集和分析关键数据,为监管部门的审批做好充分准备。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10